Otonomy Announces Phase 3 Clinical Trial Plan for OTIPRIO™ in Otitis Externa Patients Based on Successful End-of-Phase 2 Review by FDA
April 18, 2016 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, April 18, 2016 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a biopharmaceutical company focused on the development and commercialization of innovative therapeutics for diseases...
Otonomy Reports Third Quarter 2015 Financial Results and Provides Corporate Update
November 10, 2015 16:21 ET
|
Otonomy, Inc.
SAN DIEGO, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Holds Investor and Analyst Day and Provides Corporate Update
October 07, 2015 08:00 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 7, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Receives FDA Clearance of Investigational New Drug Application for Tinnitus Product Candidate, OTO-311
October 05, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Oct. 5, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy to Host Investor and Analyst Day on October 7, 2015
September 30, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 30, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC) will host an Investor and Analyst Day on Wednesday, October 7, 2015, from 8:30 a.m. to 11:30 a.m. EDT (5:30 a.m. to 8:30 a.m....
Otonomy to Present Results for AuriPro(TM) Phase 3 and OTO-104 Phase 2b Clinical Trials at 2015 AAO-HNSF Annual Meeting
September 24, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 24, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Announces Successful End-of-Phase 2 Meeting With the FDA for OTO-104 in Meniere's Disease
September 09, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 9, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Appoints Ted Schroeder to Board of Directors
September 01, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, Sept. 1, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Reports Second Quarter 2015 Financial Results and Provides Corporate Update
August 12, 2015 16:05 ET
|
Otonomy, Inc.
SAN DIEGO, Aug. 12, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (NASDAQ:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...
Otonomy Initiates Phase 2 Clinical Trial for AuriPro(TM) in Second Label Expansion Indication
July 28, 2015 07:30 ET
|
Otonomy, Inc.
SAN DIEGO, July 28, 2015 (GLOBE NEWSWIRE) -- Otonomy, Inc. (Nasdaq:OTIC), a clinical-stage biopharmaceutical company focused on the development and commercialization of innovative therapeutics for...